Search for other papers by Tristan Avril in
Google Scholar
PubMed
Search for other papers by Quentin Hennocq in
Google Scholar
PubMed
Search for other papers by Anne-Sophie Lambert in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Search for other papers by Juliane Leger in
Google Scholar
PubMed
Search for other papers by Dominique Simon in
Google Scholar
PubMed
Université Paris Cité, Faculté de Santé, UFR de Médecine, Paris, France
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Search for other papers by Laetitia Martinerie in
Google Scholar
PubMed
Inserm UMR1185, Le Kremlin Bicetre, Paris, France
Paris-Saclay University, Paris, France
Search for other papers by Claire Bouvattier in
Google Scholar
PubMed
modalities of gonadotropins administration in two groups of CHH boys, treated during the mini-pubertal period. Multi-weekly injections of recombinant human chorionic gonadotrophin (hCG) and FSH for 3 months was the first modality (injection group). Continuous
Search for other papers by Nandini Shankara Narayana in
Google Scholar
PubMed
Search for other papers by Lam P Ly in
Google Scholar
PubMed
Search for other papers by Veena Jayadev in
Google Scholar
PubMed
Search for other papers by Carolyn Fennell in
Google Scholar
PubMed
Search for other papers by Sasha Savkovic in
Google Scholar
PubMed
Search for other papers by Ann J Conway in
Google Scholar
PubMed
Search for other papers by David J Handelsman in
Google Scholar
PubMed
most common route of administration has been the parenteral injection of testosterone as a pro-drug esterified to short-chain aliphatic fatty acids in a vegetable oil vehicle ( 2 ). These injectable products are affordable with depot effects that
Search for other papers by Eric M Ndombi in
Google Scholar
PubMed
Search for other papers by Valentine Budambula in
Google Scholar
PubMed
Search for other papers by Mark K Webale in
Google Scholar
PubMed
Search for other papers by Francis O Musumba in
Google Scholar
PubMed
Search for other papers by Jesca O Wesongah in
Google Scholar
PubMed
Search for other papers by Erick Mibei in
Google Scholar
PubMed
Search for other papers by Aabid A Ahmed in
Google Scholar
PubMed
Search for other papers by Raphael Lihana in
Google Scholar
PubMed
Search for other papers by Tom Were in
Google Scholar
PubMed
Introduction Injection drug use and associated co-morbidities are an increasing public health burden in the world (1) . An estimated 15.9 million people worldwide are injection drug users (IDUs), comprising 3 and 10 million HIV and hepatitis C
Search for other papers by Cecilia Follin in
Google Scholar
PubMed
Search for other papers by Sven Karlsson in
Google Scholar
PubMed
( 9 ). In patients with acromegaly, impaired quality of life (QoL) – as assessed by specific questionnaires – has been reported even in patients who experience long-term cure ( 10 ). The chronic need for monthly injections of SSA might negatively
Search for other papers by Régis Coutant in
Google Scholar
PubMed
Pediatric team of the Clinical Investigation Center 9302/INSERM, Hospital of Children, Toulouse, France
Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France
Search for other papers by Maithé Tauber in
Google Scholar
PubMed
Search for other papers by Béatrice Demaret in
Google Scholar
PubMed
Search for other papers by Robin Henocque in
Google Scholar
PubMed
Search for other papers by Yves Brault in
Google Scholar
PubMed
Search for other papers by François Montestruc in
Google Scholar
PubMed
Patient-Reported Outcomes Unit (PROQOL), UMR 1123, University Paris Cité, INSERM, Paris, France
Search for other papers by Olivier Chassany in
Google Scholar
PubMed
Search for other papers by Michel Polak in
Google Scholar
PubMed
Search for other papers by the QOLITHOR Study Group in
Google Scholar
PubMed
improvement of psychosocial problems ( 3 , 4 ) and improvement in quality of life (QOL) ( 5 , 6 ). In addition, rhGH injections are well tolerated ( 7 , 8 ) even if adherence to treatment was shown as suboptimal ( 9 ). The majority of currently available
Search for other papers by Ashley N Reeb in
Google Scholar
PubMed
Search for other papers by Andrea Ziegler in
Google Scholar
PubMed
Search for other papers by Reigh-Yi Lin in
Google Scholar
PubMed
microenvironment. Previously, we and other laboratories developed an orthotopic thyroid cancer model that faithfully recapitulates the clinical characteristics of advanced thyroid cancer ( 1 , 2 , 3 , 4 ). In addition, tail vein or intracardiac injection models
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus C, Denmark
Search for other papers by Esben S Lauritzen in
Google Scholar
PubMed
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus C, Denmark
Search for other papers by Nikolaj Rittig in
Google Scholar
PubMed
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus C, Denmark
Search for other papers by Ermina Bach in
Google Scholar
PubMed
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus C, Denmark
Search for other papers by Niels Møller in
Google Scholar
PubMed
Search for other papers by Mette Bjerre in
Google Scholar
PubMed
), healthy and without regular intake of medicine were investigated two times: (1) After isotonic saline injection (bolus saline) and (2) after an Escherichia coli endotoxin (10,000 USP Endotoxin, lot H0K354; The United States Pharmacopeial Convention, Inc
Search for other papers by Myrtille Fouché in
Google Scholar
PubMed
Search for other papers by Yves Bouffard in
Google Scholar
PubMed
Search for other papers by Mary-Charlotte Le Goff in
Google Scholar
PubMed
Search for other papers by Johanne Prothet in
Google Scholar
PubMed
Search for other papers by François Malavieille in
Google Scholar
PubMed
Search for other papers by Pierre Sagnard in
Google Scholar
PubMed
Search for other papers by Françoise Christin in
Google Scholar
PubMed
Search for other papers by Davy Hayi-Slayman in
Google Scholar
PubMed
Search for other papers by Arnaud Pasquer in
Google Scholar
PubMed
Search for other papers by Gilles Poncet in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
EA 7426 Hospices Civils de Lyon-University Claude Bernard Lyon 1-Biomérieux ‘Pathophysiology of Injury-Induced Immunosuppression’ Pi3, Lyon, France
Search for other papers by Thomas Rimmelé in
Google Scholar
PubMed
(HR) or blood pressure (BP)) ≥40%, not explained by surgical or anaesthetic management and regressive ≥20% within 5 min after the octreotide bolus injection; probable ioCS was defined as cases for which manifestations did not meet all criteria of
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Fahim Ebrahimi in
Google Scholar
PubMed
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Sandrine A Urwyler in
Google Scholar
PubMed
Division of Endocrinology, Diabetes and Metabolism, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
Search for other papers by Philipp Schuetz in
Google Scholar
PubMed
Division of Endocrinology, Diabetes and Metabolism, University Department of Medicine, Kantonsspital Aarau, Aarau, Switzerland
Search for other papers by Beat Mueller in
Google Scholar
PubMed
Search for other papers by Luca Bernasconi in
Google Scholar
PubMed
Search for other papers by Peter Neyer in
Google Scholar
PubMed
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Marc Y Donath in
Google Scholar
PubMed
Department of Clinical Research, University of Basel Hospital, Basel, Switzerland
Search for other papers by Mirjam Christ-Crain in
Google Scholar
PubMed
anakinra, purchased by Swedish Orphan Biovitrum, or an identically appearing placebo twice-daily, as self-administered, subcutaneous injections for 4 weeks. Compliance to treatment was assessed by counting returned empty syringes, by keeping a medication
Search for other papers by Milou Cecilia Madsen in
Google Scholar
PubMed
Search for other papers by Martin den Heijer in
Google Scholar
PubMed
Search for other papers by Claudia Pees in
Google Scholar
PubMed
Search for other papers by Nienke R Biermasz in
Google Scholar
PubMed
Search for other papers by Leontine E H Bakker in
Google Scholar
PubMed
-acting intramuscular injections, such as Sustanon®, are esters of testosterone (TE) that have been used for many years for the treatment of testosterone deficiency prior to the availability of transdermal testosterone preparations. However, they have to be administered